|1.||Skorpen, Frank: 5 articles (01/2008 - 01/2006)|
|2.||Zwart, John-Anker: 5 articles (01/2008 - 01/2006)|
|3.||Hagen, Knut: 5 articles (01/2008 - 01/2006)|
|4.||Hankinson, Susan E: 5 articles (12/2006 - 05/2002)|
|5.||Hunter, David J: 5 articles (12/2006 - 05/2002)|
|6.||Tamer, Lülüfer: 4 articles (01/2015 - 11/2004)|
|7.||Zhan, Ping: 4 articles (12/2013 - 07/2010)|
|8.||Ambite-Quesada, Silvia: 4 articles (09/2013 - 10/2011)|
|9.||Qiu, Li-Xin: 4 articles (12/2010 - 06/2010)|
|10.||Zheng, Wei: 4 articles (07/2008 - 01/2004)|
|1.||Schizophrenia (Dementia Praecox)
01/01/2009 - "The [oxy-Hb] increase in the Met carriers during the verbal fluency task was significantly greater than that in the Val/Val individuals in the frontopolar prefrontal cortex of patients with schizophrenia, although neither medication nor clinical symptoms differed significantly between the two subgroups. "
02/01/2013 - "Furthermore, a genotype × diagnosis interaction was found in the left middle frontal gyrus, such that the effect of genetic risk for schizophrenia was evident in the context of the Val/Val genotype only, i.e. "
04/01/2009 - "The Val158Met polymorphism at the COMT gene was not associated with schizophrenia, although Val/Val homozygosity tended to be more frequent in the case group than in the control group (34% vs 27%; OR=1.39; 95% CI, 0.78-2.47). "
07/01/2008 - "The Val/Val genotype is associated with severer form of schizophrenia in men."
07/01/2008 - "When the group of patients has been stratified by sex and form of schizophrenia, the higher frequency of the Val/Val genotype is observed in the subgroup of men with continuous (chronic) schizophrenia as compared to men with attack-like form (p = 0.047). "
|2.||Endometrial Neoplasms (Endometrial Cancer)
03/01/2013 - "As for COMT Val158Met (rs4680) polymorphism, the heterogeneous genotype showed a decreased risk for endometrial cancer compared with the common homogenous genotype in a fixed-effect model in Asian population (Met/Val vs. Val/Val: pooled OR, 0.83; 95% CI, 0.70-0.98; P = 0.033; I = 29.2%), whereas no positive results are found in other subgroups or models. "
01/01/2013 - "In conclusion, our results suggested that the COMT Val/Val genotype might act as a potential endometrial cancer risk factor in postmenopausal women. "
02/01/2007 - "The most frequent genotype was COMT(Val/Val) (47.2%, 52/110) in control group and COMT(Val/Met) (58.3%, 77/132) in endometrial cancer group. "
04/15/2005 - "Interestingly, the relatively low frequency of Val/Val genotype in both the cancer cases and controls, in parallel with the lower incidence of endometrial cancer in Chinese, was observed when compared with those in Caucasians. "
01/01/2013 - "Although no obvious associations were detected between COMT Val158Met and endometrial cancer susceptibility in the pooled analysis, we noted significantly decreased endometrial cancer risk for Val/Met versus Val/Val, and Met/Met + Val/Met versus Val/Val genetic models in the postmenopausal female (OR = 0.795, 95%CI = 0.656-0.962, P = 0.019; and OR = 0.819, 95%CI = 0.683-0.983, P = 0.032; respectively), and similar results existed in high-quality studies (OR = 0.835, 95%CI = 0.726-0.961, P = 0.012; and OR = 0.853, 95%CI = 0.747-0.974, P = 0.019; respectively). "
08/01/2010 - "Subjective sleepiness and EEG markers of sleep homeostasis in wakefulness and sleep were equally affected by sleep deprivation in Val/Val and Met/Met allele carriers (placebo condition). "
03/01/2009 - "Two-time 100 mg modafinil potently improved vigor and well-being, and maintained baseline performance with respect to executive functioning and vigilant attention throughout sleep deprivation in Val/Val genotype subjects but was hardly effective in subjects with the Met/Met genotype. "
08/01/2015 - "Modafinil maintained executive functioning performance and vigilant attention throughout sleep deprivation in subjects with Val/Val genotype, but less in those with Met/Met genotype. "
06/01/2003 - "A dipeptide prodrug of the antiviral nucleoside acyclovir (ACV), val-val-ACV (VVACV), was evaluated in vivo as a potential drug candidate for improving antiviral efficacy against herpetic epithelial and stromal keratitis. "
06/01/2003 - "In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model."
12/01/2005 - "Val-Val-GCV (1% w/v) provided significantly better therapeutic activity than trifluorothymidine (1% w/v) against HSV-1 epithelial keratitis and equivalent therapeutic activity against stromal keratitis in the rabbit eye model. "
|5.||Cytochrome P-450 CYP1A1 (CYP1A1)
|7.||Brain-Derived Neurotrophic Factor (BDNF)
|2.||Drug Therapy (Chemotherapy)
|3.||Activities of Daily Living (ADL)